European Journal of Cancer
Volume 38 , Pages S19-S24 , December 2002

Phase II trial of ZD0473 as second-line therapy in mesothelioma

  • G Giaccone

      Affiliations

    • Free University Hospital, Amsterdam, The Netherlands
    • Tel.: +31 20 4444 352; Fax: +31 20 4444 079.
    • ,
  • M.E.R O'Brien

      Affiliations

    • Royal Marsden Hospital, Sutton, UK
    • Kent Cancer Centre, Maidstone, UK
    • ,
  • M.J Byrne

      Affiliations

    • Sir Charles Gairdner Hospital, Nedlands, Australia
    • ,
  • M Bard

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • ,
  • E Kaukel

      Affiliations

    • Allgemeines Krankenhaus Harburg, Hamburg, Germany
    • ,
  • B Smit

      Affiliations

    • Tygerberg Hospital, Tygerberg, South Africa

References 

  1. Jaklitsch MT, Grondin SC, Sugarbaker DJ. Treatment of malignant mesothelioma. World J Surg. 2001;25:210–217
  2. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 1996;14:466–480
  3. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995;345:535–539
  4. Boylan AM. Mesothelioma: new concepts in diagnosis and management. Curr Opin Pulm Med. 2000;6:157–163
  5. Boutin C, Monnet I, Ruffie P, Astoul P. Malignant mesothelioma: clinical and therapeutic study. Rev Mal Respir. 1999;16:1317–1326
  6. Lee YCG, Light RW, Musk AW. Management of malignant pleural mesothelioma: a critical review. Curr Opin Pulm Med. 2000;6:267–274
  7. Ho L, Sugarbaker DJ, Skarin AT. Malignant pleural mesothelioma. Cancer Treat Res. 2001;105:327–373
  8. Segers K, Kumar-Singh S, Weyler J, et al.  Glutathione S-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study. J Cancer Res Clin Oncol. 1996;122:619–624
  9. Krarup-Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol. 1991;28:319–330
  10. Kindler HL, Millard F, Herndon JE, Vogelzang NJ, Suzuki Y, Green MR. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001;31:311–317
  11. Alberts AS, Falkson G, Van Zyl L. Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst. 1988;80:698–700
  12. Steele JP, Shamash J, Evans MT, et al.  Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000;18:3912–3917
  13. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer. 1992;65:956–960
  14. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest. 1998;113:66S–73S
  15. Planting AS, Schellens JH, Goey SH, et al.  Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol. 1994;5:373–374
  16. Middleton GW, Smith IE, O'Brien ME, et al.  Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol. 1998;9:269–273
  17. Kelland LR, Barnard CDJ. AMD473. Drugs of the Future. 1998;23:1062–1065
  18. Gore M, Atkinson RJ, Dirix L, et al.  ZD0473 phase II monotherapy trial in second-line ovarian cancer. Eur J Cancer. 2001;37:S261; (abstr 967)
  19. Schiller J, Bonomi P, Modiano M, et al.  Activity of ZD0473 in small-cell lung cancer: an update in patients relapsing after one prior-chemotherapy regimen. Eur J Cancer. 2001;37:S62; (abstr 219)
  20. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol. 1996;14:1007–1017
  21. Parra HS, Tixi L, Latteri F, et al.  Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer. 2001;92:650–656
  22. Vogelzang NJ, Rusthoven J, Paoletti P, et al.  Phase III single-blinded study of pemetrexed + cisplatin vs cisplatin alone in chemonaive patients with malignant pleural mesothelioma. In: Proc Am Soc Clin Oncol. 21:2002;p. 2a; (abstr 5)
  23. Byrne MJ, Davidson JA, Musk AW, et al.  Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25–30
  24. Fizazi K, Caliandro R, Soulie P, et al.  Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer. 2000;36:1514–1521
  25. Steele JP, Shmash J, Evans MT, et al.  Phase II trial of vinorelbine and oxaliplatin (VO) in malignant pleural mesothelioma (MPM). In: Proc Am Soc Clin Oncol. 20:2001;p. 335a; (abstr 1335)

PII: S0959-8049(02)80018-1

European Journal of Cancer
Volume 38 , Pages S19-S24 , December 2002

Article Tools